The study objective is to demonstrate the safety of the iTind as compared to the UroLift.
1 Primary · 1 Secondary · Reporting Duration: 48 months
Experimental Treatment
250 Total Participants · 3 Treatment Groups
Primary Treatment: iTind arm · No Placebo Group · N/A
Age 50 - 80 · Male Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: